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Abstract
Objective: To study the effects of nocturnal hypoxemia in patients with chronic obstructive pulmonary disease without obstructive sleep 
apnea syndrome. Methods: We studied 21 patients—10 desaturators and 11 nondesaturators—submitted to arterial blood gas analysis, 
polysomnography, spirometry, cardiopulmonary exercise testing (cycle ergometer), and hand-grip dynamometry, as well as measurements 
of maximal inspiratory pressure, maximal expiratory pressure, and C-reactive protein (CRP) levels. Patients with arterial oxygen tension > 
60 mmHg were included; those with an apnea-hypopnea index > 5 events/hour of sleep were excluded. Maximal oxygen uptake, maximal 
power, systolic blood pressure, diastolic blood pressure (DBP), and maximal heart rate were measured during exercise in order to detect 
hemodynamic alterations. Patients presenting CRP levels above 3 mg/L were considered CRP-positive. Results: Minimum peripheral oxygen 
saturation during sleep was significantly higher among nondesaturators (p = 0.03). More desaturators presented CRP > 3 mg/L (p < 0.05). 
No differences were observed in terms of any variables. However, mean oxygen saturation during sleep correlated with DBP and maximal 
inspiratory pressure (p < 0.001 and p = 0.001, respectively). Conclusions: Although nocturnal hypoxemia does not reduce exercise capacity or 
hand-grip strength in patients with mild/moderate COPD, its effect on maximal exercise DBP seems to depend on the degree of hypoxemia. 
In addition, there is a positive relationship between maximal inspiratory pressure and mean oxygen saturation during sleep, as well as 
evidence of pronounced inflammatory activation in patients with nocturnal hypoxemia.
Keywords: Pulmonary disease, chronic obstructive; Exercise test; Anoxia; Respiratory function tests.
Resumo
Objetivo: Estudar os efeitos da hipoxemia noturna em pacientes com doença pulmonar obstrutiva crônica sem síndrome da apnéia obstrutiva 
do sono. Métodos: Estudamos 21 pacientes—10 dessaturadores e 11 não-dessaturadores—submetidos a gasometria arterial, polissonografia, 
espirometria, teste de exercício cardiopulmonar (cicloergômetro), dinamometria manual e medidas de pressão inspiratória máxima, pressão 
expiratória máxima e proteína C reativa (PCR). Incluíram-se os pacientes com pressão parcial arterial de oxigênio > 60 mmHg; excluíram-se 
os com índice de apnéia-hipopnéia > 5 eventos/hora de sono. Foram medidos consumo máximo de oxigênio, potência máxima, pressão arte-
rial sistólica, pressão arterial diastólica (PAD) e frequência cardíaca máxima durante exercício, visando detectar alterações hemodinâmicas. A 
PCR foi considerada positiva quando acima de 3 mg/L. Resultados: A saturação periférica de oxigênio mínima durante o sono foi significati-
vamente maior nos não-dessaturadores (p = 0,03). Mais dessaturadores apresentaram PCR > 3 mg/L (p < 0,05). Não houve diferença quanto 
a capacidade de exercício e demais variáveis. No entanto, PAD (p < 0,001) e pressão inspiratória máxima (p = 0,001) correlacionaram-se com 
saturação periférica de oxigênio média durante o sono. Conclusões: A hipoxemia noturna não reduz a capacidade de exercício e a força de 
preensao manual em pacientes com DPOC leve/moderada, mas o ajuste da PAD durante o exercício máximo parece depender do grau de 
hipoxemia. Além disso, há uma relação positiva entre pressão inspiratória máxima e saturação periférica de oxigênio média durante o sono, 
bem como indícios de ativação inflamatória diferenciada em pacientes com hipoxemia noturna.
Descritores: Doença pulmonar obstrutiva crônica; Teste de esforço; Anóxia; Testes de função respiratória.
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health care clinics or smoking cessation outpatient 
clinics between May of 2006 and May of 2007.
We used a modified version of the list of criteria 
established in the Global Initiative for Chronic 
Obstructive Lung Disease(19) and by the American 
Thoracic Society/European Respiratory Society task 
force for diagnosis and treatment of COPD(20): being 
between 40 and 75 years of age; being a smoker or a 
former smoker (smoking history of ≥ 20 pack-years); 
and having no orthopedic impairments or comorbid-
ities that affect exercise capacity, such as diabetes, 
heart failure, asthma, or pulmonary hypertension. 
As additional criteria, the following spirometry 
results were required: a ratio between forced expira-
tory volume in one second (FEV1) and forced vital 
capacity lower than 70%; and a postbronchodilator 
FEV1 greater than 50% of predicted. 
None of the patients participated in pulmonary 
rehabilitation programs or had used medications 
that could potentially affect exercise capacity, such 
as systemic corticosteroids or androgenic anabolic 
steroids, within the preceding 3 months. The patients 
were required to be exacerbation-free for at least 
6 weeks prior to the study and to present resting 
arterial oxygen tension (PaO2) > 60 mmHg on room 
air. All patients were informed of the objective of 
the study and the tests involved. All participating 
patients gave written informed consent. The study 
protocol was approved by the Ethics Committee of 
the Federal University of Mato Grosso do Sul..
The study was performed in three consecutive 
visits made within a single week. In the first visit, 
venous blood samples were collected (following a 
fast of at least 2 h) in order to obtain hematologic 
and biochemical variables, and anthropometry was 
performed in order to determine body mass index 
(weight in kilograms divided by height in meters 
squared)—weight measured using a scale (Welmy 
S.A., Santa Bárbara do Oeste, Brazil) calibrated 
before each measurement, and height measured 
using an appropriate stadiometer. In addition, the 
patients completed a basic questionnaire on sleep 
and underwent physical examination, after which 
spirometry was performed (Master Screen; Jaeger, 
Würtzburg, Germany, 2003). After a short interval, 
arterial blood samples were collected under anaer-
obic conditions in order to perform blood gas analysis 
(ABL 5; Radiometer, Copenhagen, Denmark).
In the second visit, overnight polysomnography 
was performed using a 32-channel device (Meditron 
Introduction
Patients with chronic obstructive pulmonary 
disease (COPD) can present oxygen desaturation 
during sleep (nocturnal desaturation), without 
obstructive sleep apnea syndrome (OSAS).(1) 
Consequently, such patients can present strong 
indications of concomitant systemic inflamma-
tion associated with the bronchial inflammatory 
process, capable of inducing abnormal oxidative 
stress,(2,3) which can be exacerbated by chronic 
daytime hypoxemia.(4) However, the systemic effects 
of nocturnal hypoxemia have been little studied in 
patients with COPD.
Intermittent nocturnal hypoxemia has been 
extensively studied in patients with OSAS, as well as 
in experimental models, and has been strongly asso-
ciated with numerous dysfunctions that affect such 
patients, such as cardiac abnormalities,(5,6) muscle 
abnormalities,(7) pulmonary arterial hypertension,(8,9) 
peripheral neuropathy,(10) and autonomic abnor-
malities.(11) All of the compartments involved are 
determinants of exercise capacity. Some authors 
have found reduced exercise capacity in patients 
with OSAS,(12,13) although others have demonstrated 
no such impairment.(14,15)
It is also known that increases in the levels of 
C-reactive protein (CRP), platelets, fibrinogen, 
and interleukin-6 are associated with nocturnal 
hypoxemia in patients with OSAS,(16) together with 
altered autonomic tone,(11) altered daytime catecho-
laminergic activity,(17) and increased diastolic blood 
pressure (DBP) during maximal exercise.(18)
Our objective in this study was to evaluate 
the impact of nocturnal oxygen desaturation on 
maximal aerobic capacity and on its hemodynamic 
alteration components, as well as to determine 
maximal respiratory pressures, maximal voluntary 
isometric contraction (MVIC) force, and compara-
tive CRP levels in patients with COPD, presenting 
normoxemia or mild hypoxemia during the day, 
with and without nocturnal oxygen desaturation.
Methods
This was a cross-sectional study involving 
21 patients with mild to moderate COPD.(19) All 
patients were referred to the COPD outpatient clinic 
of the Department of Pulmonology of the Federal 
University of Mato Grosso do Sul from primary 
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and the measurement with the highest value was 
chosen.
The measurement of maximal respiratory pres-
sures was performed, based on total lung capacity 
and residual volume, using a digital a vacuum 
manometer (MVD 300; Globalmed, Porto Alegre, 
Brazil), together with software, in accordance with 
the 2002 Pulmonary Function Test Guidelines.(23)
For the cardiopulmonary exercise testing, we 
used a cycle ergometer (Ergometrics 900; Ergoline, 
Bitz, Germany) and a mixing chamber measurement 
analyzer (Jaeger, Würtzburg, Germany), with an 
incremental protocol on a sliding scale and incre-
ments, calculated using the Wasserman formula, 
ranging from 2 to 4 W every 10 s, until maximal 
oxygen uptake during exercise (VO2max) or oxygen 
Eletromedicina Ltda., São Paulo, Brazil), in a clinic 
accredited by the Brazilian Sleep Research Society, 
according to the criteria set forth in the Brazilian 
Consensus on Sleep.(21) The term “nocturnal desatu-
rator” was used in order to define a patient presenting 
a drop in peripheral oxygen saturation (SpO2, meas-
ured using digital oximetry) that is greater than 4% 
in relation to baseline (15 min after signal stabiliza-
tion) and persists for at least 5 min, as recommended 
by Block et al.(22) Three patients were excluded from 
the study due to the nocturnal oximetry results or 
the exercise test results (underexertion).
In the third visit, we measured upper limb MVIC 
using an analog Jamar dynamometer (Sammons 
Preston; Jamar, Bolingbrook, IL, USA). A total of 
five measurements were performed on each hand, 
Table 1 - Anthropometric, demographic, pulmonary function, exercise, and polysomnography variables, together with 
C-reactive protein levels, for the sample as a whole, as well as for the desaturator and nondesaturator groups. 
Variable Sample as a 
whole (n = 21)
Group p
D (n = 10) ND (n = 11)
BMI (kg/m2) 24.8 ± 4.4 23.5 ± 3.5 26.0 ± 5.0 0.195
Age (years) 60.8 ± 7.8 62.1 ± 7.6 59.5 ± 8.2 0.469
Gender (male/female) 15/6 6/4 9/2 -
Smoking (former smoker/current smoker) 9/12 4/6 5/6 1.000
Inhaled corticosteroids (use/non-use) 9/12 4/6 5/6 1.000
FEV1 (% of predicted) 75.8 ± 18.6 77 ± 16.6 74.6 ±21.0 0.778
FVC (% of predicted) 102.9 ± 16.5 103.8 ± 14.2 102.1 ± 18.9 0.828
FEV1/FVC (%) 56.6 ± 8.8 57.6 ± 8.1 55.6 ± 9.7 0.621
MIP (% of predicted) 101.5 ± 25.4 97.7 ± 18.1 104.9 ± 31.2 0.529
MEP (% of predicted) 119.9 ± 18.9 114.2 ± 19.8 125.1 ± 17.3 0.195
PaO2 (mmHg) 76.9 ± 9.0 73.1 ± 7.3 80.3 ± 9.4 0.070
VO2max (% of predicted) 93.1 ± 15.3 89.1 ± 17.9 96.7 ± 12.4 0.267
Wmax (% of predicted) 86.5 ± 30.7 79.1 ± 31.3 93.1 ± 29.9 0.307
MESBP (mmHg) 210.8 ± 27.9 205.4 ± 35.2 215.7 ± 19.8 0.412
MEDBP (mmHg) 101.2 ± 22.2 99.4 ± 19.0 102.9 ± 25.5 0.727
MVIC (kgf) 35.5 ± 11.6 34.9 ± 13.8 36.0 ± 9.8 0.821
SpO2rest (%) 96.4 ± 1.0 96.2 ± 1.2 96.5 ± 0.7 0.860
SpO2peak (%) 94.9 ± 1.9 95.3 ± 1.5 94.5 ± 2.2 0.350
meanSpO2sleep (%) 93.7 ± 1.5 93.4 ± 1.5 93.8 ± 1.4 0.610
minSpO2sleep (%) 87.2 ± 4.7 85.1 ± 5.8 89.1 ± 2.5 0.030*
AHI (events/hour of sleep) 2.3 ± 1.8 2.4 ± 1.8 2.3 ± 1.8 0.884
CRP (≤3 mg/L/>3 mg/L) 13/8 4/6 9/2 0.045*
D: desaturators; ND: nondesaturators; BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital 
capacity; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; PaO2: arterial oxygen tension; VO2max: maximal 
oxygen uptake during exercise; Wmax: maximal power (watts) during exercise; MESBP: maximal exercise systolic blood pressure; 
MEDBP: maximal exercise diastolic blood pressure; MVIC: maximal voluntary isometric contraction; SpO2rest: peripheral oxygen 
saturation at rest; SpO2peak: SpO2 at peak exertion; meanSpO2sleep: mean SpO2 during sleep; minSpO2sleep: minimum SpO2 during 
sleep; AHI: apnea-hypopnea index; and CRP: C-reactive protein. *p < 0.05.
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The results are expressed as mean ± standard 
deviation. The Mann-Whitney test was used to 
compare the groups in terms of SpO2 during exer-
cise and during sleep. The Student’s t-test was used 
for the other numerical data, and Fisher’s exact test 
was used for nominal variables. The chi-square test 
was used to compare the groups in terms of CRP 
levels. Spearman’s linear correlation test was used to 
assess the correlation between the variables related 
to SpO2 during sleep and the other relevant vari-
ables. In addition, a partial correlation analysis was 
carried out to determine the degree of influence that 
significant variables had on a final variable—mean 
SpO2 during sleep. The primary outcome measure 
of the present study was nocturnal oxygen desatu-
ration. Considering a mean incidence of nocturnal 
oxygen desaturation of 45%,(1) it was estimated that 
the evaluation of 20 patients (10 in each group) 
uptake at peak exertion. The protocol included an 
automatic measurement of blood pressure every 
60 s using the technique of impedance plethysmog-
raphy. To that end, we used a device, calibrated and 
connected to the cycle ergometer by the manufac-
turer, with a cuff containing a sensor to determine 
blood pressure and pulse. Immediately before the 
end of, or immediately after, the exercise, a meas-
urement was made by manual computer command.
The CRP levels were measured by quantitative 
immunonephelometry (CardioPhase; Dade Behring, 
Marburg, Germany), and values below 3 mg/L were 
considered normal.(24)
The patients were divided into two groups 
(desaturators and nondesaturators) using the crite-
rion described. Patients with COPD and presenting 
an apnea-hypopnea index greater than 5 events/
hour of sleep were excluded.
Table 2 - Mean and minimum peripheral oxygen saturation during sleep: correlations with body mass index, pulmonary 
function variables, and exercise variables for the sample as a whole, as well as for the desaturator and nondesaturator 
groups. 
Variable Sample as a whole (n = 21) Group
D (n = 10) ND (n = 11)
meanSpO2sleep minSpO2sleep meanSpO2sleep minSpO2sleep meanSpO2sleep minSpO2sleep
BMI (kg/m2) r = −0.171 r = −0.105 r = −0.209 r = −0.123 r = −0.221 r = −0.159
p = 0.458 p = 0.649 p = 0.562 p = 0.735 p = 0.514 p = 0.641
FEV1 (L) r = 0.535 r = 0.472 r = 0.560 r = 0.615 r = 0.529 r = 0.424
p = 0.012* p = 0.031* p = 0.092 p = 0.058 p = 0.094 p = 0.193
FEV1 (% of 
predicted)
r = 0.435 r = 0.231 r = 0.345 r = 0.462 r = 0.558 r = 0.250
p = 0.049* p = 0.314 p = 0.329 p = 0.179 p = 0.075 p = 0.458
VO2max (% of 
predicted)
r = 0.304 r = 0.068 r = 0.080 r = −0.031 r = 0.561 r = −0.009
p = 0.180 p = 0.769 p = 0.826 p = 0.933 p = 0.073 p = 0.978
Wmax (% of 
predicted)
r = 0.489 r = 0.084 r = 0.351 r = 0.135 r = 0.501 r = 0.233
p = 0.025* p = 0.718 p = 0.320 p = 0.709 p = 0.116 p = 0.490
MESBP (mmHg) r = 0.073 r = 0.000 r = 0.166 r = 0.062 r = −0.221 r = 0.266
p = 0.754 p = 1.000 p = 0.646 p = 0.866 p = 0.513 p = 0.428
MEDBP (mmHg) r = −0.449 r = −0.255 r = −0.935 r = −0.695 r = −0.235 r = 0.306
p = 0.041* p = 0.266 p = 0.000** p = 0.026* p = 0.487 p = 0.360
MVIC (kgf) r = 0.353 r = 0.259 r = 0.201 r = 0.315 r = 0.518 r = 0.220
p = 0.116 p = 0.257 p = 0.578 p = 0.376 p = 0.102 p = 0.516
MIP (% of 
predicted)
r = 0.529 r = 0.551 r = 0.866 r = 0.598 r = 0.308 r = 0.462
p = 0.014* p = 0.010* p = 0.001** p = 0.068 p = 0.357 p = 0.153
MEP (% of 
predicted)
r = −0.089 r = 0.191 r = −0.222 r = −0.086 r = 0.083 r = 0.229
p = 0.701 p = 0.408 p = 0.538 p = 0.813 p = 0.809 p = 0.499
D: desaturators; ND: nondesaturators; meanSpO2sleep: mean peripheral oxygen saturation during sleep; minSpO2sleep: minimum 
SpO2 during sleep; BMI: body mass index; FEV1: forced expiratory volume in one second; VO2max: maximal oxygen uptake during 
exercise; Wmax: maximal power during exercise (watts); MESBP: maximal exercise systolic blood pressure; MEDBP: maximal exercise 
diastolic blood pressure; MVIC: maximal voluntary isometric contraction; MIP: maximal inspiratory pressure; and MEP: maximal 
expiratory pressure. *p < 0.05. **p < 0.01.
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correlations with those two variables were signifi-
cant when we considered the sample as a whole, we 
found no such correlations when we analyzed the 
nondesaturator group separately (Table 2).
In the sample as a whole, FEV1 in liters (r = 0.535; 
p = 0.012) and FEV1 in percentage of predicted 
(r = 0.435; p = 0.049) were found to present a close, 
positive correlation with mean SpO2 during sleep. In 
addition, FEV1 in liters (r = 0.472; p = 0.031) was 
found to present a close, positive correlation with 
minimum SpO2 during sleep (Table 2).
Discussion
In our study, there were no differences between 
the two groups in terms of exercise capacity in the 
cycle ergometer test. There were a significantly 
greater number of patients with CRP levels above 
the normal values in the desaturator group, and, 
in this group, DBP during maximal exercise on the 
cycle ergometer adjusted, inversely and closely, to 
mean SpO2 during sleep.
The effect of nocturnal oxygen desaturation 
on exercise capacity has previously been studied in 
patients with OSAS. Some studies have revealed no 
reduction in aerobic capacity on the cycle ergometer 
test,(12,13) whereas others have reported a signifi-
cant reduction.(14,15) One study showed a significant 
increase in VO2max after the use of noninvasive 
support ventilation.(25) However, in those studies, 
would allow exploratory associative analyses among 
the principal variables of interest. Values of p < 0.05 
were considered statistically significant. The statis-
tical analysis was carried out using the Statistical 
Package for the Social Sciences, version 13.0 for 
Windows (SPSS Inc., Chicago, IL, USA).
Results
In the period from May of 2006 to May of 2007, 
we studied 21 patients—6 (29%) of whom were 
female—divided into two groups: desaturators and 
nondesaturators. The anthropometric and demo-
graphic data, as well as data on polysomnography 
results, pulmonary function, and CRP levels, are 
shown in Table 1, which presents total values and 
values for each of the two groups.
We found a statistically significant difference 
between the two groups in terms of minimum SpO2 
during sleep (p = 0.03), and the number of patients 
presenting CRP levels above those considered normal 
was significantly greater in the desaturator group 
(Table 1). Values for the exercise variables were, on 
average, slightly lower in the desaturator group, 
although the differences were not significant. No 
significant differences were found between the 
groups in terms of being a smoker/former smoker 
or the use/non-use of inhaled corticosteroids 
(Table 1).
In the sample as a whole (n = 21), there was 
a significant positive correlation between maximal 
power during exercise (in watts) and mean SpO2 
during sleep (p = 0.025). However, this statistical 
significance did not hold after the partial correla-
tion analysis with PaO2 at rest as a control variable 
(r = 0.219; p = 0.354). The two groups presented 
minimum SpO2 during sleep greater than that found 
at peak exertion (Table 1).
No significant differences were found between 
the groups in terms of peripheral strength as meas-
ured by MVIC (p = 0.821; Table 1), and this variable 
did not correlate with the parameters of nocturnal 
SpO2 for the groups separately (Table 2).
Although there was no statistical difference 
between the groups in terms of mean SpO2 during 
sleep, this variable correlated, inversely and closely, 
with DBP during maximal exercise (p < 0.001; 
r = −0.935; Figure 1) and, directly, with maximal 
inspiratory pressure (MIP; p = 0.001; r = 0.866; 
Figure 2) in the desaturator group. Although the 
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Figure 1 - Correlation between maximal exercise diastolic 
blood pressure (MEDBP) and mean peripheral oxygen 
saturation (SpO2) during sleep.
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by respiratory muscles, indicating that, on average, 
the patients in the desaturator group maintain 
their capacity to generate strength preserved when 
compared to those in the nondesaturator group. We 
point out that MIP (% of predicted) correlated with 
mean SpO2 during sleep in the sample as a whole 
and, especially, in the desaturator group, corrob-
orating findings in the literature.(26) It is known, 
however, that high-intensity training of the respira-
tory musculature can reduce the depth of nocturnal 
oxygen desaturation,(27) although this was not the 
case in our patients.
There were no differences between the groups 
in terms of maximal exercise systolic blood pres-
sure or DBP during maximal exercise, although the 
desaturator group presented a good correlation 
between DBP during maximal exercise and mean 
SpO2 during sleep, as has been reported in studies 
involving patients with OSAS.(15,18) We can speculate 
that this correlation might be an initial presentation 
of the systemic arterial hypertension that develops 
in patients with nocturnal oxygen desaturation, 
since the autonomic dysfunction in blood pres-
sure control, due to upregulation of the baroreflex 
controlled by carotid bodies, has been well estab-
lished in experimental models and clinical studies 
of OSAS.(11)
Oxidative stress is certainly a factor related to 
intermittent hypoxemia. Markers of oxidative stress 
are increased in patients with OSAS, and they 
decrease after treatment with noninvasive support 
ventilation.(25)
Another consistent effect of intermittent hypox-
emia, associated with oxidative stress, is increased 
serum levels of biomarkers, such as CRP. The fact 
that the desaturator group presented a significantly 
greater number of patients with CRP levels above 
the normal cut-off value is consistent with studies 
on OSAS,(16) despite the fact that the groups did not 
differ in terms of smoking, use of inhaled corticos-
teroids, or body mass index, all of which are factors 
that could affect the results. Levels of CRP are of 
prognostic importance in patients with COPD(28) and 
correlate statistically with the distance covered on 
the six-minute walk test,(29) as well as constituting a 
significant and independent predictor of endurance 
on the submaximal cycle ergometer test in patients 
with COPD.(29)
Correlations between individual spirometry 
variables and mean SpO2 during sleep have been 
patients were not studied in terms of peripheral 
strength or respiratory muscle strength. In addition, 
the desaturation criterion differs between the two 
diseases. In patients with OSAS, hypoxemic episodes 
last 15-45 s, whereas, in patients with COPD, such 
episodes last for more than 5 min, as in our study.
Patients with COPD have well-known mechanisms 
of limitations of exercise capacity. In our study, the 
values of exercise variables were slightly lower, on 
average, in the desaturator group patients, although 
there were no significant differences between the 
two groups. Despite the positive, significant corre-
lation between maximal power and mean SpO2 
during sleep, this significance did not hold after the 
partial correlation analysis with daytime PaO2 as a 
control variable, unlike the close correlation found 
between VO2max and minimum SpO2 during sleep 
in 12 patients with OSAS.(17)
The desaturation found during maximal exercise 
in relation to rest was quite low (an average of 1%) 
compared to the much more significant desatura-
tion during sleep, with a mean 9% drop in SpO2. It 
is estimated that cardiovascular stress during sleep 
can be, in some cases, even more intense than that 
reached during maximal exercise.(1) Nevertheless, 
nocturnal oxygen therapy is not indicated as 
frequently as is oxygen therapy during exercise.(19)
The groups did not differ in terms of peripheral 
strength as measured by MVIC or strength generated 
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Figure 2 - Correlation between maximal inspiratory 
pressure (MIP) and mean peripheral oxygen saturation 
(SpO2) during sleep.
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established by some authors,(1,30) and, in our case, 
FEV1 correlated with mean SpO2 during sleep. 
However, the former is not an important predictor 
of nocturnal hypoxemia in studies.
Among the limiting factors of this study is the 
fact that fat-free mass, which could better charac-
terize a relationship between exercise capacity and 
nocturnal hypoxemia, was not measured. Another 
limiting factor is the desaturation criterion adopted. 
Although some authors recommend using a 10% 
drop in saturation or saturation below 90% during 
more than 30% of total sleep time,(1) we followed 
the recommendation of Block et al.(22) since this was 
a study involving patients with mild to moderate 
COPD, in whom those criteria would rarely be met.
Therefore, we conclude that mild nocturnal 
hypoxemia does not reduce exercise capacity in 
patients with mild to moderate COPD. However, 
its effect on DBP during maximal exercise seems 
to depend on the intensity of nocturnal oxygen 
desaturation, and MIP in percentage of predicted 
correlates with mean SpO2 during sleep. In addition, 
there is evidence of greater systemic inflammatory 
activation (determined by measuring CRP levels) 
in patients with COPD who present desaturation 
during sleep.
As a clinical implication, we suggest that patients 
with mild to moderate COPD be better investigated 
as to the need for oxygen supplementation during 
sleep.
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